增强的MAPK信号对CSF3R诱导的白血病至关重要
该研究通过小鼠模型发现,CSF3R近膜突变和复合突变(近膜与截短突变位于同一等位基因)可致白血病,疾病潜伏期分别为90天和23天;截短突变单独不能诱导白血病。Mapk衔接蛋白Ksr1诱导表达及Mapk信号增强对白血病发生至关重要;曲美替尼抑制Mek1/2可抑制近膜突变及对芦可替尼耐药的复合突变所诱导的白血病。
要点
- CSF3R近膜突变与复合突变可致白血病,潜伏期分别为90天和23天;截短突变单独不致病。
- Ksr1诱导表达和Mapk信号增强是CSF3R近膜及复合突变致白血病的关键。
- 曲美替尼抑制Mek1/2可抑制近膜突变及对芦可替尼耐药的复合突变诱导的白血病。
核心结论
- CSF3R近膜突变和复合突变通过Mapk依赖机制诱导白血病,为MEK1/2抑制在慢性中性粒细胞白血病(CNL)中的临床评估提供了依据。
研究设计与样本
- 研究采用小鼠模型,比较CSF3R截短突变、近膜突变和复合突变(近膜与截短突变位于同一等位基因)的白血病诱导能力,并进行全基因组表达谱分析和生化实验。
主要发现
- 截短突变单独不能诱导白血病;近膜突变和复合突变可致白血病,疾病潜伏期分别为90天和23天。
- 全基因组表达谱分析和生化实验显示,Mapk衔接蛋白Ksr1的诱导表达及Mapk信号增强对CSF3R近膜和复合突变致白血病至关重要。
- 曲美替尼抑制Mek1/2可抑制CSF3R近膜突变和对芦可替尼耐药的复合突变所诱导的白血病。
临床怎么用
- 作者认为这些发现为MEK1/2抑制在CNL中的临床评估提供了依据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Both membrane-proximal and truncation mutations in CSF3R have recently been reported to drive the onset of chronic neutrophilic leukemia (CNL). Here we show that although truncation mutation alone cannot induce leukemia, both proximal and compound mutations (proximal and truncation mutations on same allele) are leukemogenic with a disease latency of 90 and 23 days, respectively. Comparative whole-genome expression profiling and biochemical experiments revealed that induced expression of Mapk adaptor protein Ksr1 and enhanced Mapk signaling are crucial to leukemogenesis by CSF3R proximal and compound mutants. Moreover, inhibition of Mek1/2 by trametinib alone is sufficient to suppress leukemia induced by both CSF3R proximal and ruxolitinib-resistant compound mutations. Together, these findings elucidate a Mapk-dependent mechanism of CSF3R-induced pathogenesis, and they establish the rationale for clinical evaluation of MEK1/2 inhibition in CNL.
引用
- Rohrabaugh S, Kesarwani M, Kincaid Z, et al. Enhanced MAPK signaling is essential for CSF3R-induced leukemia. Leukemia. 2016. PMID: 28031554. doi:10.1038/leu.2016.376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。